Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q06643 (
non-Hodgkin's lymphoma
)
11,307
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The last four decades have seen a significant increase in the incidence of
non-Hodgkin's lymphoma
(
NHL
) as a possible result of increasing environmental carcinogen exposure, particularly pesticides and solvents. Based on the increasing evidence for an association between carcinogen exposure-related cancer risk and xenobiotic gene polymorphisms, we have undertaken a case-control study of xenobiotic gene polymorphisms in individuals with a diagnosis of
NHL
. Polymorphisms of six xenobiotic genes (CYP1A1, GSTT1, GSTM1,
PON1
, NAT1, NAT2) were characterized in 169 individuals with
NHL
and 205 normal controls using polymerase chain reaction-based methods. Polymorphic frequencies were compared using Fisher's exact tests, and odds ratios for
NHL
risk were calculated. Among the
NHL
group, the incidence of GSTT1 null and
PON1
BB genotypes were significantly increased compared with controls, 34% vs 14%, and 24% vs 11% respectively. Adjusted odds ratios calculated from multivariate analyses demonstrated that GSTT1 null conferred a fourfold increase in
NHL
risk (OR = 4.27; 95% CI, 2.40-7.61, P < 0.001) and
PON1
BB a 2.9-fold increase (OR = 2.92; 95% CI, 1.49-5.72, P = 0.002). Furthermore, GSTT1 null combined with
PON1
BB or GSTM1 null conferred an additional risk of
NHL
. This is the first time that a
PON1
gene polymorphism has been shown to be associated with cancer risk. We conclude that the two polymorphisms, GSTT1 null and
PON1
BB, are common genetic traits that pose low individual risk but may be important determinants of overall population
NHL
risk, particularly among groups exposed to
NHL
-related carcinogens.
...
PMID:Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. 1213 35
Epidemiologic studies have failed to establish clearly whether agricultural pesticides contribute to the genesis of
non-Hodgkin's lymphoma
(
NHL
). Discordant results may be related to variation in susceptibility factors, including metabolism gene polymorphisms that might influence lymphocyte exposures to active pesticide metabolites. Associations between
NHL
and polymorphisms that may be relevant to pesticide metabolism have been assessed, including CYP1A1 and glutathione S-transferase variants, but the results are not highly informative because estimates were based on small numbers and convenience samples of cases and controls. Butyrylcholinesterase and paraoxonase (
PON1
) enzyme variants associated with altered activity and acute organophosphate toxicity are strong candidate susceptibility factors for pesticides and
NHL
, but others may be identified as knowledge of pesticide metabolism and relevant polymorphisms improves. Studies of metabolic susceptibility must be large and include information on specific exposures and subtypes of
NHL
for results to further the understanding of the relation between agricultural pesticides and
NHL
.
...
PMID:Metabolic susceptibility to agricultural pesticides and non-Hodgkin's lymphoma. 1619 Jan 46
Genes involved in metabolism of environmental chemical exposures exhibit sequence variability that may mediate the risk of
non-Hodgkin's lymphoma
. We evaluated associations between
non-Hodgkin's lymphoma
and 15 variants in AHR, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2E1, GSTP1, GSTM3, EPHX1, NQO1, and
PON1
. Cases were identified from four Surveillance, Epidemiology, and End Results registries in the United States, and population-based controls were identified through random-digit dialing and Medicare eligibility files. Metabolic gene variants were characterized for the 1,172 (89% of total) cases and 982 (93%) controls who provided biological samples for genotyping. Subjects who were heterozygous or homozygous for the cytochrome P450 gene variant CYP1B1 V432L G allele were at slightly greater risk of
non-Hodgkin's lymphoma
[odds ratio (OR), 1.27; 95% confidence interval (95% CI), 0.97-1.65]; these results were consistent across B-cell lymphoma subtypes and among both non-Hispanic White and Black subjects, although not statistically significant. The CYP2E1 -1054T allele was associated with decreased risk of
non-Hodgkin's lymphoma
(CT and TT genotypes combined OR, 0.59; 95% CI, 0.37-0.93), and this pattern was observed among all histologic subtypes. The numbers of cases of particular subtypes were rather small for stable estimates, but we noted that the
PON1
L55M AA allele, associated with slightly increased risk of
non-Hodgkin's lymphoma
(variant homozygotes OR, 1.36; 95% CI, 0.96-1.95), was most strongly associated with follicular
non-Hodgkin's lymphoma
and T-cell lymphoma, with ORs for variant homozygotes of 2.12 and 2.93, respectively. There was no overall association with
non-Hodgkin's lymphoma
for the other gene variants we examined. The modest effects we observed may reflect the context of exposures within the general population represented in our study.
...
PMID:Metabolic gene variants and risk of non-Hodgkin's lymphoma. 1698 26